title: Mesenchymal stromal cell therapy in liver disease: opportunities and lessons to be learnt?
abstract: End-stage liver disease is responsible for 30,000 deaths per year in the United States alone, and it is continuing to increase every year. With liver transplantation the only curative treatment currently available, new therapies are in great demand. Mesenchymal stem cells (MSC) offer an opportunity to both treat liver inflammatory damage, as well as reverse some of the changes that occur following chronic liver injury. With the ability to regulate both the innate and adaptive immune system, as well as both inhibit and promote apoptosis of effector inflammatory cells, there are numerous therapeutic opportunities for MSC in acute and chronic liver disease. This article critically appraises the potential therapeutic roles of MSC in liver disease, as well as the barriers to their adoption into clinical practice.
authors: National Institute for Health Research Birmingham Liver Biomedical Research Unit and Centre for Liver Research, Birmingham, United Kingdom; and.
authors: Andrew
authors: 0000-0002-3192-747X
authors: A
authors: Owen
authors: National Institute for Health Research Birmingham Liver Biomedical Research Unit and Centre for Liver Research, Birmingham, United Kingdom; and Liver Unit, University Hospital Birmingham National Health Service Foundation Trust, Birmingham, United Kingdom. P.N.Newsome@bham.ac.uk
authors: Philip N
authors: PN
authors: Newsome
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000502:physiology; D002986:Clinical Trials as Topic; D006801:Humans; D056747:Immunomodulation / Q000276:immunology; D007249:Inflammation / Q000276:immunology / Q000628:therapy; D008107:Liver Diseases / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells / Q000502:physiology*
keywords: liver disease; mesenchymal stem cell; mesenchymal stromal cell